|Composition||Telmisartan 80/ 40/ 20 mg tablets|
|Indication||Hypertension, Cardiovascular risk reduction|
|Mechanism of Action||
Telmisartan is a nonpeptide AT1 angiotensin II receptor antagonist. It exerts antihypertensive activity by preventing angiotensin II from binding to AT1 receptors thus inhibiting the vasoconstricting and aldosterone-secreting effects of angiotensin II.
Onset: 1-2 hr.
Duration: Up to 24 hr.
Absorption: Rapidly absorbed from the GI tract. Food may slightly decrease the bioavailability. Absolute bioavailability: Dose-dependent (approx 42% after 40-mg dose; 58% after 160-mg dose). Time to peak plasma concentration: Approx 0.5-1 hr.
Distribution: Volume of distribution: 500 L. Plasma protein binding: >99%.
Metabolism: Undergoes conjugation w/ glucuronic acid to form inactive metabolites
Excretion: Via faeces (97%, as unchanged drug). Terminal elimination half-life: Approx 24 hr.
Dizziness, fatigue, headache, sinusitis, upper resp tract infection, pharyngitis, UTI, back pain, myalgia, diarrhoea, abdominal pain, dyspepsia, nausea. Potentially Fatal: Intermittent claudication and skin ulcer.
Volume- or salt-depleted patients including patients on prolonged diuretic therapy. Patients w/ renal artery stenosis, aortic or mitral stenosis, obstructive biliary disease. Renal and mild to moderate hepatic impairment. Lactation. Monitoring Parameters Monitor BP, electrolytes and serum creatinine levels.
HTN Initial: 40 mg once daily, may be adjusted to 20-80 mg once daily. CV risk reduction 80 mg once daily.